Companion Diagnostics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The Report Covers the Companion Diagnostics Market Share and Size. The Market is Segmented by Technology (Immunohistochemistry (IHC), Polymerase Chain Reaction (PCR), In-Situ Hybridization (ISH), Real-Time PCR (RT-PCR), Gene Sequencing, and Other Technologies), Indication (Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Melanoma, and Other Indications), and Geography (North America (United States, Canada, and Mexico), Europe (Germany, United Kingdom, France, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia-Pacific), Middle East and Africa (GCC, South Africa, and the Rest of Middle East and Africa), and South America (Brazil, Argentina, and Rest of South America)). The Report Offers Value (in USD Million) for the Abovementioned Segments.

Companion Diagnostics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Companion Diagnostics Industry Overview

The companion diagnostics market is highly fragmented and competitive, with several major players. The rising focus of companies on personalized medicine, co-development activities, and increased cases of adverse drug reactions are expected to boost the market's competitive nature. Some of the key players in the market are Abbott, Agilent Technologies Inc., F Hoffmann-La Roche Ltd, Biomerieux, Qiagen NV, and Siemens Healthineers AG.

Companion Diagnostics Market Leaders

  1. Qiagen NV

  2. Agilent Technologies Inc.

  3. Abbott

  4. Biomerieux

  5. F. Hoffmann-La Roche Ltd

  6. *Disclaimer: Major Players sorted in no particular order
Companion Diagnostics Market Concentration

Companion Diagnostics Market Report Snapshots

80% of our clients seek made-to-order reports. How do you want us to tailor yours?